NEW YORK (GenomeWeb News) – The Federal Trade Commission has cleared the way for GE Healthcare's purchase of molecular diagnostics and imaging firm Clarient.
The FTC this week granted GE Healthcare early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, removing antitrust barriers in the US to the cash deal, estimated at $570 million to $580 million.
The proposed acquisition was announced in October. At the time, GE Healthcare said that its diagnostic imaging capabilities combined with Clarient's technologies would hasten development of new integrated tools for diagnosing and characterizing cancer. It added that the global market for cancer-profiling products and services is forecast to increase to $47 million by 2015 from $15 million in 2009.
GE Healthcare has said the deal is expected to close later this year or early in 2011.